I. Resource Base: Why Guangxi Earns the "Natural Medicine Storehouse" Label

Situated at the intersection of tropical and subtropical zones, Guangxi benefits from abundant heat and rainfall that have cultivated China's second-largest reservoir of traditional medicine resources — over 4,600 species of medicinal plants, animals, and minerals, trailing only Yunnan. On this resource foundation, Guangxi's pharmaceutical manufacturing industry has developed along three clear trajectories: TCM brand manufacturing centered on Guilin, medicinal herb trade centered on Yulin, and a distinctive Zhuang-Yao ethnic medicine system.

Guangxi is also recognized as one of China's four major producing regions for authentic medicinal herbs. Official data shows the region's cultivated medicinal herb area has long held around 6 million mu. The Zhuang-Yao ethnic medicine resources are particularly notable — the Chinese Zhuang Medicine Resource Catalog (2014 edition) records more than 2,285 species of Zhuang medicinal resources. Guangxi's pharmaceutical regulatory authority has issued quality standards covering 490 Zhuang medicine varieties and 314 Yao medicine varieties. (Source: Guangxi Zhuang Autonomous Region Administration of Traditional Chinese Medicine)

II. Geographic Clusters: Industrial Division Among Nanning, Guilin, and Yulin

Guangxi's pharmaceutical manufacturing is not evenly distributed; instead it reflects a clear inter-city division of labor.

Guilin is the heartland of TCM brand manufacturing. Guilin Sanjin Pharmaceutical (SZSE: 002275) and Guangxi Golden Throat (headquartered in Liuzhou) are the region's most nationally recognized TCM names. Guilin is also the global center of monk fruit production: Yongfu County alone cultivates more than 132,000 mu of monk fruit, with over 100 processing enterprises and a full-chain output exceeding 10 billion yuan. Ninety percent of the world's monk fruit is processed here, with products exported to the US, EU, Japan, and South Korea. (Source: Xinhua Silk Road, Guilin Daily Life)

Yulin serves as the circulation hub. Yulin Yinfeng International TCM Port is one of China's first eight nationally approved professional TCM markets, and Guangxi's only national-level medicinal herb market. It hosts more than 3,000 traders dealing in over 4,000 species. In 2023, total transaction volume reached 12.7 billion yuan, with 380 new business registrations. The China Association of Traditional Chinese Medicine has officially granted Yulin the title "Southern Medicine Capital." (Source: Guangxi Agriculture and Rural Affairs Department)

Nanning is the policy and capital hub for modern biopharmaceuticals. The Nanning Economic and Technological Development Zone hosts 705 biopharmaceutical enterprises, with a portfolio spanning biopharmaceuticals, TCM, medical devices, and pharmaceutical logistics. The Guangxi Department of Industry and Information Technology has formulated a program targeting 100 billion yuan in biopharmaceutical output. (Source: Xinhua Guangxi, Guangxi DIIT)

III. Leading Enterprises: Three National-Level Brands

Guangxi's pharmaceutical manufacturing identity is largely carried by three enterprises.

Guilin Sanjin Pharmaceutical is among the largest listed pharmaceutical companies in the region, founded in 1967 (originally Guilin Chinese Medicine Factory). Its flagship Watermelon Frost series sells more than 2.5 billion tablets annually, commanding approximately 20% of China's throat and oral medicine market; the Sanjin Tablet series sells over 1.8 billion tablets annually with more than 30% share in the anti-urinary tract infection TCM segment, generating annual revenues exceeding 400 million yuan. (Source: EAST MONEY Securities Research Report 2023)

Guangxi Golden Throat is headquartered in Liuzhou and ranks among China's top 50 pharmaceutical manufacturers. Annual production capacity of Golden Throat Lozenges reaches 5 billion units with output value around 1 billion yuan. In 2022, Golden Throat Lozenges led the throat TCM retail market with sales exceeding 700 million yuan. (Source: China Non-prescription Drug Association)

Yulin Pharmaceutical (subsidiary of China Shineway Pharmaceutical Group, HKEX: 1681.HK) traces its history to the Yulin Pharmaceutical Factory founded in 1956 and holds a "China Time-Honored Brand" designation. Its flagship Zhenggu Shui (bone-setting liniment) is a national geographic indication product, and Yunxiang Jing and other external preparations are exported to over 30 countries. Annual production and sales exceed 500 million yuan, with capsule capacity of 1.85 billion units per year. (Source: Guangxi Commerce Department)

IV. Supply Chain: A Relatively Closed Loop from Raw Herb to Finished Product

A defining characteristic of Guangxi's pharmaceutical industry is its relative self-sufficiency in upstream raw materials.

Upstream cultivation includes monk fruit, cinnamon, and magnolia bark from Guilin; honeysuckle from Hechi; dendrobium from Hezhou; and star anise and amomum from Yulin. Guilin city alone has 570,000 mu under cultivation with annual dry herb output of 200,000 tonnes — the highest among all Guangxi prefectures. (Source: Guangxi Agriculture and Rural Affairs Department)

The midstream distribution layer is anchored by Yulin's Yinfeng TCM Port, which functions as a pricing center and redistribution node for raw materials destined for manufacturers across South China and beyond.

The downstream manufacturing layer is dominated by oral TCM preparations (liquids, capsules, tablets) with a distinctive external-use preparation niche (liniments, tinctures). Around 160 above-scale pharmaceutical manufacturers generate a combined output of approximately 31.3 billion yuan, with TCM preparations accounting for more than half. Nanning and Guilin together account for over half of the provincial pharmaceutical total. (Source: Guangxi DIIT)

V. Challenges: Ethnic Medicine Standardization and the Innovation Gap

Guangxi's pharmaceutical sector faces several structural headwinds.

The first is product concentration risk. Sanjin Tablet, Watermelon Frost, and Golden Throat Lozenges are mature multi-decade products. Under centralized procurement pressure and emerging competition, leading firms must cultivate new growth without disrupting their existing franchise — a challenge common across the sector.

The second is the standardization barrier facing Zhuang-Yao ethnic medicines. While Guangxi has established quality standard frameworks, ethnic medicines are largely confined to hospital-compounded preparations and face narrow pathways toward national drug approval. The timeline from verified traditional formula to approved market product routinely exceeds ten years. (Source: Guangxi Drug Regulatory Bureau)

The third is international compliance pressure on botanical extracts. Guilin has become the world's largest monk fruit processing and export base, but tightening EU and US standards for residues and additives in monk fruit sweetener extracts continue to raise compliance costs for exporters. (Source: Guilin Daily Life, Chinanews)

VI. Research Observations

Guangxi's pharmaceutical industry stands apart because it is not a pure manufacturing cluster but a relatively complete "resource–circulation–brand" triangle: Yulin provides raw material flow, Guilin and Liuzhou produce nationally recognized TCM brands, and Nanning absorbs modern biopharmaceutical policy attention and capital. This structure gives Guangxi a meaningful end-to-end position in the TCM segment, but in chemical drugs, biologics, and advanced medical devices, the gap with Guangdong, Zhejiang, and Sichuan remains substantial. Whether Guangxi can convert its Zhuang-Yao ethnic medicine resources into industrializable new drug assets will be a decisive variable in whether the industry can break through its current output ceiling.

Sales teams supplying pharmaceutical raw materials, packaging, equipment, or distribution services — and seeking verified factory-type clients in Guangxi — can use Tianxia Gongchang to filter Guangxi pharmaceutical manufacturers by region and industry, accessing contact information for decision-makers and reducing time spent on unqualified leads.

Data Sources

  • Tianxia Gongchang (Guangxi pharmaceutical manufacturing factory directory and industry data)
  • Guangxi Zhuang Autonomous Region Administration of Traditional Chinese Medicine (Zhuang-Yao medicine quality standards, industry policy documents)
  • Guangxi Department of Industry and Information Technology (Billion-yuan biopharmaceutical target program, cluster development plan)
  • Guangxi Agriculture and Rural Affairs Department (TCM industry overview, Yulin "Southern Medicine Capital" reports)
  • Guangxi Drug Regulatory Bureau (Ethnic medicine regulation and standardization)
  • Guangxi Commerce Department (Yulin Zhenggu Shui geographic indication product)
  • EAST MONEY Securities Research Report (Guilin Sanjin initiation report, 2023)
  • China Non-prescription Drug Association (Guangxi Golden Throat enterprise profile)
  • Xinhua Silk Road (Guilin monk fruit full-chain output value data)
  • Chinanews (Guilin monk fruit export base report, 2021)
  • Xinhua Guangxi (Nanning ETDZ biopharmaceutical industry report, 2023)